[1] Abenavoli L, Greco M, Milic N,et al. Effect of mediterranean diet and antioxidant formulation in non-alcoholic fatty liver disease: a randomized study. Nutrients, 2017,9(8):870.
[2] Campanella A, Iacovazzi PA, Misciagna G, et al.The effect of three mediterranean diets on remnant cholesterol and non-alcoholic fatty liver disease: a secondary analysis. Nutrients, 2020, 12(6):1674.
[3] Gao Y, Lu J, Liu X, et al. Effect of long-term exercise on liver lipid metabolism in chinese patients with NAFLD: a systematic review and meta-analysis. Front Physiol, 2021,12: 748517.
[4] O′Gorman P, Naimimohasses S, Monaghan A, et al. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther, 2020, 52(8): 1387-1398.
[5] Weng Z, Ou W, Huang J, et al. Circadian misalignment rather than sleep duration is associated with MAFLD: a population-based propensity score-matched study. Nat Sci Sleep, 2021, 13: 103-111.
[6] Usman M, Bakhtawar N. Vitamin E as an adjuvant treatment for non-alcoholic fatty liver disease in adults: a systematic review of randomized controlled trials. Cureus, 2020, 12(7): e9018.
[7] Abdel-Maboud M, Menshawy A, Menshawy E, et al. The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Therap Adv Gastroenterol, 2020, 13: 1756284820974917.
[8] Green CJ, Marjot T, Walsby-Tickle J, et al. Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. Eur J Endocrinol, 2022, 186(3): 367-377.
[9] Mantovani A, Byrne CD, Scorletti E, et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab, 2020, 46(6): 427-441.
[10] Della PG, Russo M, Vitale M, et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract, 2021, 178: 108984.
[11] Nesti L, Tricò D, Mengozzi A, et al. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol, 2021,20(1): 109.
[12] Yang TH, Xirasagar S, Cheng YF, et al. Association between pioglitazone use and head and neck cancer: Population-based case-control study. Head Neck, 2020, 42(4): 653-659.
[13] Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med, 2021, 384(12): 1113-1124.
[14] Flint A, Andersen G, Hockings P,et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther, 2021, 54(9): 1150-1161.
[15] Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, et al. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol, 2021, 36(10): 2952-2959.
[16] Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab, 2019, 21(2): 285-292.
[17] Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2019, 394(10215): 2184-2196.
[18] Siddiqui M.S, Van Natta ML, Connelly MA, et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatol, 2020, 72(1): 25-33.
[19] Lee J.I, Lee HW, Lee KS, et al. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study. Am J Gastroenterol, 2021, 116(1): 116-124.
[20] Hajifathalian K, Tafesh Z, Rosenblatt R, et al. Effect of statin use on cancer-related mortality in nonalcoholic fatty liver disease: a prospective united states cohort study. J Clin Gastroenterol, 2022, 56(2): 173-180.
[21] Pastori D, Pani A, Di Rocco A, et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br J Clin Pharmacol, 2022, 88(2): 441-451.
[22] Kobyliak N, Abenavoli L, Mykhalchyshyn G, et al. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in nafld patients: evidence from a randomized clinical trial. J Gastrointestin Liver Dis, 2018, 27(1): 41-49.
[23] Mohamad NM, Ayob N, Mokhtar NM, et al. The effect of probiotics (MCP(?) BCMC(?) Strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease. Nutrients, 2021, 13(9): 3192.
[24] Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol, 2020, 115(7): 1055-1065.
[25] Salomone F, Currenti W, Magrì G, et al. Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis. Liver Int, 2021, 41(9): 2112-2116.
[26] Chandan S, Mohan BP, Khan SR, et al. Efficacy and safety of intragastric balloon (IGB) in non-alcoholic fatty liver disease (NAFLD): a comprehensive review and meta-analysis. Obes Surg, 2021, 31(3): 1271-1279.
[27] Zhou H, Luo P, Li P, et al. Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis. Obes Surg, 2022, 32(6):1872-1883.
[28] Pedersen JS, Rygg MO, Serizawa RR, et al. Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: a 12-month follow-up study with paired liver biopsies. J Clin Med, 2021, 10(17): 3783.
[29] Bai J, Jia Z, Chen Y, et al. Bariatric surgery is effective and safe for obese patients with compensated cirrhosis: a systematic review and meta-analysis. World J Surg, 2022, 46(5): 1122-1133.
[30] Pastore A, Panera N, Mosca A, et al. Changes in total homocysteine and glutathione levels after laparoscopic sleeve gastrectomy in children with metabolic-associated fatty liver disease. Obes Surg, 2022, 32(1): 82-89.
[31] Gao H, Zhou L, Zhong Y, et al. Kindlin-2 haploinsufficiency protects against fatty liver by targeting Foxo1 in mice. Nat Commun, 2022, 13(1): 1025.
[32] Chen L, Wu N, Kennedy L, et al. Inhibition of secretin/secretin receptor axis ameliorates NAFLD phenotypes. Hepatology, 2021, 74(4): 1845-1863.
[33] Jin Z, Sun Y, Yang T, et al. Nanocapsule-mediated sustained H(2) release in the gut ameliorates metabolic dysfunction-associated fatty liver disease. Biomaterials, 2021, 276: 121030. |
